In 2024, Lotus Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Lotus Pharmaceutical has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 2,672.054a | 3,310.317a | 10,662a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 12,842.99a | 12,129.576a | 10,647a | |
Total Scope 3 | N/A | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 4.7102a | 5.9884a | 22.3903a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Lotus Pharmaceutical amounted to 15,515.044 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Lotus Pharmaceutical increased by 0.49%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2024, the total Scope 1 emissions of Lotus Pharmaceutical were 2,672.054 metric tons of CO₂ equivalent (tCO₂e).a
Since 2022, Lotus Pharmaceutical's Scope 1 emissions have decreased by 74.94%, reflecting a declining long-term trend in Scope 1 emissions over time.a
Compared to the previous year (2023), Lotus Pharmaceutical's Scope 1 emissions decreased by 19.28%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2024, Lotus Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 12,842.99 tCO₂e without specifying the calculation method.a
Since 2022, Lotus Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 20.63%, reflecting a rising long-term trend in Scope 2 emissions over time.a
Compared to the previous year (2023), Lotus Pharmaceutical's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Lotus Pharmaceutical's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2024, Lotus Pharmaceutical reported its Scope 2 emissions using an unspecified methodology.a
In 2024, Lotus Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 2,672.054 tCO₂e and total revenues of USD 567 millions. This translates into an emissions intensity of 4.71 tCO₂e per millions USD.a
In 2024, Lotus Pharmaceutical reported a Scope 1 emissions intensity of 4.71 tCO₂e per millions USD. Compared to the peer group median of 13.09, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2024, Lotus Pharmaceutical ranked 7 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Lotus Pharmaceutical is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a